The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000617369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/04/2026
Date registered
Help: Date registered
19/05/2026
Date last updated
Help: Date last updated
19/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Periacetabular Osteotomy and Co-designed rehabilitation versus Co-designed rehabilitation in adolescents and young adults with hip dysplasia: a randomised controlled trial.
Scientific title
A randomised controlled trial comparing Periacetabular Osteotomy and Co-designed rehabilitation versus Co-designed rehabilitation on pain outcomes at 12 months, in adolescents and young adults with hip dysplasia.
Additional trial identifiers [1] 315368 0
Medical Research Future Fund Grant #2030986.
Universal Trial Number (UTN)
Trial acronym
HOpE (Hip Osteotomy surgery and Exercise) study
Related trial records

Health condition
Health condition(s) studied:
Hip dysplasia 338861 0
Condition category
Condition code
Musculoskeletal 335148 335148 0 0
Other muscular and skeletal disorders
Surgery 335149 335149 0 0
Surgical techniques
Physical Medicine / Rehabilitation 335150 335150 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
PAO Surgery and co-designed rehabilitation:
PAO surgery is performed by expert orthopaedic surgeons in usual practice, and will be performed by these surgeons at participating treatment hospitals (partner-hospitals), using contemporary, best practice procedures (Reimer, L. et al, 2019). PAO surgery typically lasts 2-3 hours. Following PAO, patients remain in hospital four to five nights with restricted weight-bearing prior to commencing gentle mobility exercises. The PAO surgery will be followed by best practice post-operative rehabilitation, which will commence after 2 weeks, once clearance from the surgeon has been obtained at the routine post-operative surgeon review. Weight-bearing restrictions determined by the surgeon, will be incorporated into the Co-designed rehabilitation program.
Registered physiotherapists will lead the targeted rehabilitation program intervention to be delivered over the 12-month period, described using the Template for Intervention Description and Replication (TIDieR) guidelines. The PAO surgery group post-operative rehabilitation intervention is the same co-designed rehabilitation program as that provided to the control group. It is a patient-centered, exercise program informed by the Danish adult Developmental Dysplasia of the Hip (DDH) randomised controlled trial (RCT) led by CI Mechlenburg (Reimer, L. et al, 2019), modified for adolescent participants and the Australian healthcare system following input from consumers, including guidance on its feasibility and appropriateness. It targets known functional impairments in those with DDH (O'Brien, M. et al, 2021). Participants will set individual goals and be educated regarding safe return to physical activity.
The Co-designed rehabilitation program includes three face-to-face and twelve further face-to-face/video physiotherapy consultations over 12 months. The first session is an extended initial (60 minute) consultation (pre-operatively and occurring within two weeks of planned surgery for the surgical group) to commence all non-weightbearing exercises and commence postural sway correction training. All subsequent sessions are 30 minutes (occurring post-operatively for the surgical group). The extended-initial, two and six week sessions will be face-to-face but for all other sessions, telehealth will be offered. In Phases 1-3 participants perform 1-2 unsupervised select movement pattern training exercises, daily. In Phase 3 participants perform one unsupervised strength training session weekly, progressing to two sessions in Phases 4-5. Weight-bearing restrictions are incorporated into the co-designed rehabilitation program and both groups perform the same exercises, but the surgery group commences two to four weeks post-surgery.
The approximate timeframes are as follows:
• Phase 1 refers to pre-surgery to 6-8 weeks post-op (surgical group) or baseline to weeks 4-6 (non-surgical group).
• Phase 2 then refers to the following weeks up to week 10 for both groups.
• Phase 3 refers to weeks 10 to weeks 12-14.
• Phase 4 refers to approximately week 14 to week 18.
• Phase 5 (the final phase) then refers to week 20 onwards.
Phase 1-4 progressions are based on acceptable pain levels (no increase >2/10) and time and Phase 5 progressions are based on rate of perceived exertion (RPE 5-6).
The focus areas for the various phases are as follows:
Phase 1
o Activation of key muscle groups (non-weightbearing e.g. sidelying hip abduction)
o Movement pattern retraining: ensure good standing posture and weight transfer (semi-weightbearing)
Phase 2
o Weightbearing uniplanar pattern retraining (full weightbearing) e.g. drinking bird
o Low-risk gym exercises (e.g. calf raises)
Phase 3 refers to weeks 10 to weeks 12-14
o Multiplanar movements (e.g. windmills)
o Single-leg progressions (e.g. single leg control and step)
o Strengthening gym-type exercises (e.g. bodyweight lunges)
Phase 4
o Multiplanar single-leg movements with added complexity (e.g. triple extension drive)
o Strengthening gym-type exercises (double-leg and single-leg) (e.g. squats)
Phase 5 (the final phase) then refers to week 20 onwards
o Sport specific rehabilitation-choice of 3 streams depending on sport (e.g. high-speed running stream, change of direction stream and conditioning stream). The Co-designed, five-phase rehabilitation program will be provided by experienced physiotherapists trained in the study rehabilitation protocol. All participants will receive weekly text messages to enhance adherence and motivation, as recommended by our consumer steering committee (Nelligan, R. et al, 2019). Fidelity checks of treatment sessions and auditing of treatment notes will take place.
Screws remain in place until 4-12 months post operatively as is routine best practice internationally.
In addition to Co-designed rehabilitation, all participants will receive a 60 minutes assessment by a registered mental health clinician, occurring within two weeks of intervention commencement dates for both groups (pre-operatively for the surgery group, and before the first physio appointment for the rehab group). The mental health clinician will also provide an educational intervention session (60 minutes) before the study intervention (pre-operatively for the surgery group and before the physio appointment for the rehab group). A 30-minute follow-up educational intervention session, will occur post-operatively for the surgery group and after physiotherapy commencement for the rehab group. All mental health sessions will be delivered via zoom. If the initial assessment raises concerns about the participant’s mental health, they will be referred to their general practitioner for evaluation. A mental health care plan may be provided if considered appropriate by the general practitioner. The additional support of a mental health clinician was requested by our consumer group as a critical element of the rehabilitation treatment package.
Intervention code [1] 332012 0
Treatment: Surgery
Intervention code [2] 332013 0
Rehabilitation
Description of the comparator or control
Co-designed Rehabilitation:
Registered physiotherapists will lead the targeted intervention to be delivered over the 12-month period, described using the Template for Intervention Description and Replication (TIDieR) guidelines. The control group co-designed rehabilitation intervention is the same as that provided to the PAO surgery group post-operatively. It is a patient-centered, exercise program informed by the Danish adult Developmental Dysplasia of the Hip (DDH) randomised controlled trial (RCT) led by CI Mechlenburg (Reimer, L. et al, 2019), modified for adolescent participants and the Australian healthcare system following input from consumers, including guidance on its feasibility and appropriateness. It targets known functional impairments in those with DDH (O'Brien, M. et al, 2021). Participants will set individual goals and be educated regarding safe return to physical activity.
The Co-designed rehabilitation program includes three face-to-face and twelve further face-to-face/video physiotherapy consultations over 12 months. The first session is an extended initial (60 minute) consultation (pre-operatively and occurring within two weeks of planned surgery for the surgical group) to commence all non-weightbearing exercises and commence postural sway correction training. All subsequent sessions are 30 minutes (occurring post-operatively for the surgical group). The extended-initial, two and six week sessions will be face-to-face but for all other sessions, telehealth will be offered. In Phases 1-3 participants perform 1-2 unsupervised select movement pattern training exercises, daily. In Phase 3 participants perform one unsupervised strength training session weekly, progressing to two sessions in Phases 4-5. Weight-bearing restrictions are incorporated into the co-designed rehabilitation program and both groups perform the same exercises, but the surgery group commences two to four weeks post-surgery.
The approximate timeframes are as follows:
• Phase 1 refers to pre-surgery to 6-8 weeks post-op (surgical group) or baseline to weeks 4-6 (non-surgical group).
• Phase 2 then refers to the following weeks up to week 10 for both groups.
• Phase 3 refers to weeks 10 to weeks 12-14.
• Phase 4 refers to approximately week 14 to week 18.
• Phase 5 (the final phase) then refers to week 20 onwards.
Phase 1-4 progressions are based on acceptable pain levels (no increase >2/10) and time and Phase 5 progressions are based on rate of perceived exertion (RPE 5-6).
The focus areas for the various phases are as follows:
Phase 1
o Activation of key muscle groups (non-weightbearing e.g. sidelying hip abduction)
o Movement pattern retraining: ensure good standing posture and weight transfer (semi-weightbearing)
Phase 2
o Weightbearing uniplanar pattern retraining (full weightbearing) e.g. drinking bird
o Low-risk gym exercises (e.g. calf raises)
Phase 3 refers to weeks 10 to weeks 12-14
o Multiplanar movements (e.g. windmills)
o Single-leg progressions (e.g. single leg control and step)
o Strengthening gym-type exercises (e.g. bodyweight lunges)
Phase 4
o Multiplanar single-leg movements with added complexity (e.g. triple extension drive)
o Strengthening gym-type exercises (double-leg and single-leg) (e.g. squats)
Phase 5 (the final phase) then refers to week 20 onwards
o Sport specific rehabilitation-choice of 3 streams depending on sport (e.g. high-speed running stream, change of direction stream and conditioning stream)
The Co-designed, five-phase rehabilitation program will be provided by experienced physiotherapists trained in the study rehabilitation protocol. All participants will receive weekly text messages to enhance adherence and motivation, as recommended by our consumer steering committee (Nelligan, R. et al, 2019). Fidelity checks of treatment sessions and auditing of treatment notes will take place.
In addition to Co-designed rehabilitation, all participants will receive a 60 minutes assessment by a registered mental health clinician, occurring within two weeks of intervention commencement dates for both groups (pre-operatively for the surgery group, and before the first physio appointment for the rehab group). The mental health clinician will also provide an educational intervention session (60 minutes) before the study intervention (pre-operatively for the surgery group and before the physio appointment for the rehab group). A 30-minute follow-up educational intervention session, will occur post-operatively for the surgery group and after physiotherapy commencement for the rehab group. All mental health sessions will be delivered via zoom. If the initial assessment raises concerns about the participant’s mental health, they will be referred to their general practitioner for evaluation. A mental health care plan may be provided if considered appropriate by the general practitioner. The additional support of a mental health clinician was requested by our consumer group as a critical element of the rehabilitation treatment package.
Control group
Active

Outcomes
Primary outcome [1] 342817 0
Hip pain
Timepoint [1] 342817 0
Baseline and 12 months post-intervention commencement.
Secondary outcome [1] 452248 0
Hip-related quality of life
Timepoint [1] 452248 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [2] 452249 0
Hip pain
Timepoint [2] 452249 0
Baseline, weekly VAS up to and including 12-months post intervention commencement
Secondary outcome [3] 452250 0
Hip-related symptoms
Timepoint [3] 452250 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [4] 452251 0
Health-related quality of life
Timepoint [4] 452251 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [5] 452252 0
Kinesiophobia
Timepoint [5] 452252 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [6] 452253 0
Work and activity impairment
Timepoint [6] 452253 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [7] 452254 0
Emotional and mental stress, anxiety and depression as a composite outcome.
Timepoint [7] 452254 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [8] 452255 0
Insomnia
Timepoint [8] 452255 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [9] 452256 0
Patient acceptability of symptoms
Timepoint [9] 452256 0
3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [10] 452257 0
Perceived recovery
Timepoint [10] 452257 0
3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [11] 452258 0
Adherence to the exercise intervention
Timepoint [11] 452258 0
6 and 12 months post-intervention commencement.
Secondary outcome [12] 452259 0
Adverse events and complications
Timepoint [12] 452259 0
Monthly up to and including 12-months post intervention commencement
Secondary outcome [13] 452260 0
Medication use
Timepoint [13] 452260 0
Baseline, 3, 6, 12 and 18-months post intervention commencement
Secondary outcome [14] 452261 0
Treatment beliefs, perceptions, experiences, adherence, barriers and facilitators to implementation.
Timepoint [14] 452261 0
12-months post-intervention commencement
Secondary outcome [15] 452262 0
Expectations about treatment success.
Timepoint [15] 452262 0
Baseline and 12-and 18-months post intervention commencement
Secondary outcome [16] 452263 0
Cost-effectiveness of clinical management
Timepoint [16] 452263 0
Weekly until 12-months post intervention commencement
Secondary outcome [17] 452264 0
Hip joint structure (cartilage lesion presence and severity)
Timepoint [17] 452264 0
Baseline, 18-months post intervention commencement
Secondary outcome [18] 452265 0
Gait features during walking running
Timepoint [18] 452265 0
Baseline, 18-months post intervention commencement
Secondary outcome [19] 452266 0
Hip isometric strength impairments
Timepoint [19] 452266 0
Baseline, 18-months post intervention commencement
Secondary outcome [20] 458670 0
Current activity/sport participation
Timepoint [20] 458670 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [21] 460291 0
Hip-related quality of life
Timepoint [21] 460291 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [22] 460292 0
Hip-related quality of life
Timepoint [22] 460292 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [23] 460293 0
Hip pain
Timepoint [23] 460293 0
Baseline, 3, 6 and 18 months post intervention commencement
Secondary outcome [24] 460294 0
Hip-related physical function in daily living
Timepoint [24] 460294 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [25] 460299 0
Hip-related physical function in sport and recreation.
Timepoint [25] 460299 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [26] 460300 0
Hip-related physical function in physical activity.
Timepoint [26] 460300 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [27] 460313 0
Hip joint forces during walking running
Timepoint [27] 460313 0
Baseline, 18-months post intervention commencement
Secondary outcome [28] 460318 0
Hip range of motion impairment
Timepoint [28] 460318 0
Baseline, 18-months post intervention commencement
Secondary outcome [29] 460321 0
Hip function impairment
Timepoint [29] 460321 0
Baseline, 3, 6, 12 and 18-months post-intervention commencement.
Secondary outcome [30] 461278 0
Hip joint structure (cartilage composition)
Timepoint [30] 461278 0
Baseline, 18 months post-intervention.
Secondary outcome [31] 461509 0
Classroom activity impairment
Timepoint [31] 461509 0
Baseline, then 3, 6, 12 and 18 months after intervention commencement

Eligibility
Key inclusion criteria
Girls/women and boys/men,
Aged 10-40 years,
Symptomatic hip dysplasia considered appropriate for periacetabular osteotomy (PAO) by orthopaedic surgeon,
Pain >2/10 on numeric rating scale (NRS) for >3 months,
Radiographic lateral centre-edge angle 11-24 degrees,
Able to provide a signed and dated informed consent form / has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.
Minimum age
10 Years
Maximum age
40 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Radiographic osteoarthritis (greater than Kellgren Lawrence grade 1),
Prior hip surgery on the affected hip, or neurological or other systemic arthritis conditions,
Planned bilateral PAO surgery in next 12 months,
Unable to perform testing procedures,
Unable to commit to the treatment and assessment program,
Contraindications to imaging,
Unable to communicate in English,
Unwilling or unable to provide informed consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The allocation sequence will be sequentially numbered and concealed via an electronic password-controlled system (My Clinical Data), with back-up of sequence stored in the La Trobe University RDS, accessed only by the independent statistician and the La Trobe Clinical Trials Platform.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A statistician not directly involved in the analysis of the trial results will be engaged by the La Trobe University Clinical Trials Platform to prepare the computer-generated randomisation schedule. Permuted block randomisation will be used (1:1 ratio). The schedule will be held by the La Trobe University Clinical Trials Platform.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
We powered this study for our primary outcome of hip pain (Reimer, L. et al 2019), as prioritised by consumer steering committee, who said they wanted 10-points greater improvement in pain with surgery + co-designed rehabilitation, compared to an co-designed rehabilitation-only treatment. In our prior work, patients with DDH listed for PAO scored a mean of 50 (SD 18) points on our primary outcome(Jacobsen, J. et al, 2017). A 10-points greater improvement would also achieve the MCD for this measure. A 10-points greater improvement with PAO surgery (e.g. 75) compared to co-designed rehabilitation-only (e.g. 65) (O'Brien, M. et al, 2022), equates to an effect size of 0.5. To achieve this effect size, where PAO surgery + co-designed rehabilitation is superior to co-designed rehabilitation only, power of 0.80, 2-sided significance level a=0.05, the sample size required for each intervention group is 51 patients. 126 patients (63 per group) allows for possible crossovers and loss to follow-up of 20%. This sample size does not provide sufficient power for secondary endpoints, hence all secondary analyses will be exploratory.

Quantitative primary and secondary analyses

All data will be analysed by intention-to-treat with all randomised participants included in analyses, regardless of protocol adherence or cross-over. For the primary outcome, hierarchical mixed models with random effects on study site and individual participant will be used to obtain the estimate of the treatment effect (and associated 95% CI) on pain at the primary end-point at 12 months. CACE analyses will be conducted to determine causal estimates of the effects of intervention for individuals who comply with treatment. The complier average causal effects will be estimated using a two-stage least squares approach. Secondary outcomes will be evaluated using the same methods. Adverse events will be compared between groups using appropriate generalised linear models for binary and count outcomes. All primary and secondary outcomes are listed above.

Economic evaluation: to estimate the incremental cost-effectiveness (cost per Quality-adjusted Life Year (QALY)). A detailed Health Economics Analysis Plan (HEAP) will be developed prior to commencement of data analysis. Briefly, health-related QoL is collected via the reliable and valid EQ-5D-5L (Herdman, M. et al, 2011), with a published Australian value set used to derive health utility scores (Norman, R. et al, 2023). We are using the EQ-5D-5L adult form for all participants including adolescents. This will enable us to get consistent follow-up for 10–16-year-old participants who become adults during the follow-up time period. The questionnaire will be used at baseline, 6-, 12- and 18-months to permit calculation of QALYs using an area under the curve approach. Healthcare resource utilisation, including the surgical and co-designed rehabilitation interventions and co-interventions, will be collected from several sources to facilitate data analysis, reporting and corroboration. Data sources include participant healthcare utilisation questionnaires, the clinical trial database, and the MBS and PBS databases. The weekly SMS/phone calls will facilitate accurate completion of the patient questionnaires.

Qualitative interviews of up to 20 patients/parents from both treatment intervention groups and 20 clinicians (including both surgeons and physiotherapists) will occur at the primary endpoint. Participants will be selected using purposive sampling. We will explore: (i) treatment beliefs, perceptions, and experiences; (ii) factors influencing adherence to the co-designed rehabilitation intervention and whether these mediate outcomes, and (iii) patient- and clinician-perceived barriers and facilitators to implementation and adoption of surgery and co-designed rehabilitation, including participants who cross over or don’t adhere to interventions.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,WA,VIC
Recruitment hospital [1] 28499 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [2] 28500 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [3] 28501 0
The Avenue Private Hospital - Windsor
Recruitment hospital [4] 28502 0
The Alfred - Melbourne
Recruitment hospital [5] 28503 0
Epworth Richmond - Richmond
Recruitment hospital [6] 28504 0
Epworth Hospital Geelong - Waurn Ponds
Recruitment hospital [7] 28505 0
Barwon Health - Geelong Hospital campus - Geelong
Recruitment hospital [8] 28506 0
Warringal Private Hospital - Heidelberg
Recruitment hospital [9] 28507 0
Joan Kirner Women’s and Children’s Hospital - St Albans
Recruitment hospital [10] 28508 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [11] 28509 0
Perth Children's Hospital - Nedlands
Recruitment hospital [12] 28510 0
Hollywood Private Hospital - Nedlands
Recruitment hospital [13] 28511 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [14] 28512 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [15] 28513 0
Mater Private Hospital Brisbane - South Brisbane
Recruitment hospital [16] 28514 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [17] 28515 0
Womens and Childrens Hospital - North Adelaide
Recruitment hospital [18] 29291 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [19] 29292 0
Western Hospital - Footscray - Footscray
Recruitment postcode(s) [1] 44734 0
3052 - Parkville
Recruitment postcode(s) [2] 44735 0
3084 - Heidelberg
Recruitment postcode(s) [3] 44736 0
3181 - Windsor
Recruitment postcode(s) [4] 44737 0
3004 - Melbourne
Recruitment postcode(s) [5] 44738 0
3121 - Richmond
Recruitment postcode(s) [6] 44739 0
3216 - Waurn Ponds
Recruitment postcode(s) [7] 44740 0
3220 - Geelong
Recruitment postcode(s) [8] 44741 0
3021 - St Albans
Recruitment postcode(s) [9] 44742 0
6009 - Nedlands
Recruitment postcode(s) [10] 44743 0
4101 - South Brisbane
Recruitment postcode(s) [11] 44744 0
5000 - Adelaide
Recruitment postcode(s) [12] 44745 0
5006 - North Adelaide
Recruitment postcode(s) [13] 45611 0
5042 - Bedford Park
Recruitment postcode(s) [14] 45612 0
3011 - Footscray

Funding & Sponsors
Funding source category [1] 319955 0
Government body
Name [1] 319955 0
Australian Department of Health, Disability and Ageing, Medical Research Future Fund
Country [1] 319955 0
Australia
Primary sponsor type
University
Name
La Trobe University
Address
Country
Australia
Secondary sponsor category [1] 324436 0
None
Name [1] 324436 0
Address [1] 324436 0
Country [1] 324436 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318489 0
The Royal Children’s Hospital Human Research Ethics Committee
Ethics committee address [1] 318489 0
Ethics committee country [1] 318489 0
Australia
Date submitted for ethics approval [1] 318489 0
04/09/2025
Approval date [1] 318489 0
16/12/2025
Ethics approval number [1] 318489 0
HREC/120191/RCHM-2025

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144366 0
Prof Joanne Kemp
Address 144366 0
La Trobe University, Plenty Road, Bundoora, Vic 3086
Country 144366 0
Australia
Phone 144366 0
+61 3 9479 1428
Fax 144366 0
Email 144366 0
Contact person for public queries
Name 144367 0
Dr Michael O'Brien
Address 144367 0
La Trobe University, Plenty Road, Bundoora, Vic 3086
Country 144367 0
Australia
Phone 144367 0
+61 3 9479 2520
Fax 144367 0
Email 144367 0
m.o'[email protected]
Contact person for scientific queries
Name 144368 0
Professor Joanne Kemp
Address 144368 0
La Trobe University, Plenty Road, Bundoora, Vic 3086
Country 144368 0
Australia
Phone 144368 0
+61 3 9479 1428
Fax 144368 0
Email 144368 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Costs, response times, institutional policy



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.